Monotherapy is adequate for septic shock due to gram-negative organisms

Critical Care Medicine

Volumn 45, Issue 11, 2017, Pages 1930-1932

  Klompas, Michael ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; COMBINATION DRUG THERAPY; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; HUMAN; MONOTHERAPY; MORTALITY RATE; NOTE; PRIORITY JOURNAL; SEPTIC SHOCK; GRAM NEGATIVE INFECTION; INAPPROPRIATE PRESCRIBING; INTENSIVE CARE; META ANALYSIS (TOPIC); MICROBIOLOGY; MORTALITY;

ANTI-BACTERIAL AGENTS; CRITICAL CARE; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INAPPROPRIATE PRESCRIBING; META-ANALYSIS AS TOPIC; SHOCK, SEPTIC;

EID: 85045652453     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000002678     Document Type: Note

References (33)

1. Hranjec T, Rosenberger LH, Swenson B, et al: Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: A quasi-experimental, before and after observational cohort study. Lancet Infect Dis 2012; 12:774-780
2. Chastre J, Wolff M, Fagon JY, et al; PneumA Trial Group: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 2003; 290:2588-2598
3. Uranga A, España PP, Bilbao A, et al: Duration of antibiotic treatment in community-acquired pneumonia: A multicenter randomized clinical trial. JAMA Intern Med 2016; 176:1257-1265
4. de Jong E, van Oers JA, Beishuizen A, et al: Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, open-label trial. Lancet Infect Dis 2016; 16:819-827
5. Sawyer RG, Claridge JA, Nathens AB, et al: Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med 2015; 372:1996-2005
6. Klein Klouwenberg PM, Cremer OL, van Vught LA, et al: Likelihood of infection in patients with presumed sepsis at the time of intensive care unit admission: A cohort study. Crit Care 2015; 19:319
7. Chalmers JD, Rother C, Salih W, et al: Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: A systematic review and meta-analysis. Clin Infect Dis 2014; 58:330-339
8. Jones BE, Jones MM, Huttner B, et al: Trends in antibiotic use and nosocomial pathogens in hospitalized veterans with pneumonia at 128 medical centers, 2006-2010. Clin Infect Dis 2015; 61:1403-1410
9. Kalil AC, Metersky ML, Klompas M, et al: Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61-e111
10. Tenner S, Baillie J, DeWitt J, et al; American College of Gastroenterology: American College of Gastroenterology guideline: Management of acute pancreatitis. Am J Gastroenterol 2013; 108:1400-15; 1416
11. Rhodes A, Evans LE, Alhazzani W, et al: Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017; 45:486-552
12. Heyland DK, Dodek P, Muscedere J, et al; Canadian Critical Care Trials Group: Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008; 36:737-744
13. Micek ST, Welch EC, Khan J, et al: Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: A retrospective analysis. Antimicrob Agents Chemother 2010; 54:1742-1748
14. Brunkhorst FM, Oppert M, Marx G, et al; German Study Group Competence Network Sepsis (SepNet): Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: A randomized trial. JAMA 2012; 307:2390-2399
15. Paul M, Lador A, Grozinsky-Glasberg S, et al: Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2014:CD003344
16. Ocampo PS, Lázár V, Papp B, et al: Antagonism between bacteriostatic and bactericidal antibiotics is prevalent. Antimicrob Agents Chemother 2014; 58:4573-4582
17. Bollenbach T: Antimicrobial interactions: Mechanisms and implications for drug discovery and resistance evolution. Curr Opin Microbiol 2015; 27:1-9
18. Tapper ML, Armstrong D: Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: A progress report. J Infect Dis 1974; 130(Suppl):S14-S23
19. Hilf M, Yu VL, Sharp J, et al: Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540-546
20. Kuikka A, Valtonen VV: Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998; 17:701-708
21. Mendelson MH, Gurtman A, Szabo S, et al: Pseudomonas aeruginosa bacteremia in patients with AIDS. Clin Infect Dis 1994; 18:886-895
22. Siegman-Igra Y, Ravona R, Primerman H, et al: Pseudomonas aeruginosa bacteremia: An analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998; 2:211-215
23. Safdar N, Handelsman J, Maki DG: Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519-527
24. Chamot E, Boffi El Amari E, Rohner P, et al: Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47:2756-2764
25. Peña C, Suarez C, Ocampo-Sosa A, et al; Spanish Network for Research in Infectious Diseases (REIPI): Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: A post Hoc analysis of a prospective cohort. Clin Infect Dis 2013; 57:208-216
26. Bowers DR, Liew YX, Lye DC, et al: Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2013; 57:1270-1274
27. Ong DSY, Frencken JF, Klein Klouwenberg PMC, et al; MARS consortium: Short-course adjunctive gentamicin as empirical therapy in patients with severe sepsis and septic shock: A prospective observational cohort study. Clin Infect Dis 2017; 64:1731-1736
28. Hu Y, Li L, Li W, et al: Combination antibiotic therapy versus monotherapy for Pseudomonas aeruginosa bacteraemia: A meta-analysis of retrospective and prospective studies. Int J Antimicrob Agents 2013; 42:492-496
29. Kumar A, Safdar N, Kethireddy S, et al: A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta-regression study. Crit Care Med 2010; 38:1651-1664
30. Kumar A, Zarychanski R, Light B, et al; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group: Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis. Crit Care Med 2010; 38:1773-1785
31. Liang SY, Kumar A: Empiric antimicrobial therapy in severe sepsis and septic shock: Optimizing pathogen clearance. Curr Infect Dis Rep 2015; 17:493
32. Kalil AC, Johnson DW, Lisco SJ, et al: Early goal-directed therapy for sepsis: A novel solution for discordant survival outcomes in clinical trials. Crit Care Med 2017; 45:607-614
33. Shaw PA: Combination versus monotherapy for septic shock patients. Crit Care Med 2010; 38:1905-1906